GlassScriptPhysician profile
Vasavi Kavuri
NPI 1477531861
$4,123.72
in general payments reported to CMS, 2019-2025
38 companies · $599 in 2025
The $599 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $661 · 2020: $266 · 2021: $573 · 2022: $464 · 2023: $727 · 2024: $833 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,145 · Entertainment: $13.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,145.07 |
| Entertainment | $13.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $844.87 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $642.34 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $240.00 | 2019-2025 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $239.92 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $231.66 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.90 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $186.47 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $181.13 | 2019-2023 | |
| Abbvie INC. | $160.19 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.35 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $107.63 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $93.42 | 2019-2025 | Seglentis, Livalo, Zoryve |
| Esperion Therapeutics, INC. | $90.55 | 2021-2025 | Nexletol |
| Sanofi Pasteur INC. | $75.19 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $62.86 | 2024-2025 | Voquezna |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vasavi Kavuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.